Boston Partners Cuts Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• Boston Partners has reduced its stake in Catalyst Pharmaceuticals by 1.3%, now holding approximately 1.05% of the company valued at $30.6 million after selling 16,543 shares.
• Despite Boston Partners' reduction, several institutional investors, including GAMMA Investing LLC and Summit Investment Advisors Inc., have increased their stakes, highlighting ongoing interest in the biopharmaceutical firm.
• The stock price of Catalyst Pharmaceuticals is currently $20.07 with analysts rating it as "Buy" on average, indicating positive market sentiment despite a recent slight decline of 0.6% in stock value.

Boston Partners cut its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 1.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,275,325 shares of the biopharmaceutical company's stock after selling 16,543 shares during the period. Boston Partners owned about 1.05% of Catalyst Pharmaceuticals worth $30,628,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Park Square Financial Group LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth $29,000. Sound Income Strategies LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the first quarter worth $64,000. GAMMA Investing LLC increased its stake in shares of Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after purchasing an additional 579 shares in the last quarter. Quarry LP purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth $104,000. Finally, New Vernon Capital Holdings II LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth $122,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Up 0.4%

CPRX stock traded up $0.09 during trading on Wednesday, hitting $20.34. The company had a trading volume of 694,968 shares, compared to its average volume of 1,477,242. The firm has a market capitalization of $2.49 billion, a P/E ratio of 12.33, a PEG ratio of 0.82 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.00 and a 52-week high of $26.58. The company has a 50 day simple moving average of $21.41 and a 200-day simple moving average of $22.64.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on CPRX. Wall Street Zen cut shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Saturday, August 9th. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Two research analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $33.20.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 2,324 shares of the firm's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total transaction of $61,376.84. Following the transaction, the insider owned 42,681 shares of the company's stock, valued at approximately $1,127,205.21. This trade represents a 5.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 10.40% of the company's stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.